GSK Overview - Global
GSK has several social and medical initiatives for under served populations including Smiles For Kinds, Comic Relief, and Save The Children. They invested $4.95 billion in R&D last year and had $39.83 billion in revenue. They are heavily focused on cancer curing technologies and vaccine development.
- GSK's values are Patient Focus, Transparency, Respect, and Integrity. Their expectations are Courage, Accountability, Development, and Teamwork.
- They have 46 new medicines in development, 33 are targeting the immune system.
- They are state their current purpose is to develop new medical innovations, vaccines, consumer healthcare products, improve global health, improve R&D for infectious diseases, and focusing on HIV & TB health, tackling antimicrobial resistance and preparing for pandemic outbreaks is also a priority concern.
- There are "17 immuno-0ncology assets in clinical development".
- In 2018, they invested $4.95 billion in R&D.
- According to Hoovers, they have 99,817 employees, $74 billion in assets, a net income growth of 124%, and $39.83 billion in revenue for 2018.
- The pharmaceutical market is extremely competitive. Johnston & Johnston, Roche, Pfizer, Novartis, Merk, Sanofi, Bayer, Amgen, Gilead, and Sinopharm Group are all considered competitors in this market. Their revenue for 2017 is as follows: (GSK's 2017 revenue was $40.7 billion)
- Johnson & Johnson- $62.9 billion
- Pfizer- $52 billion
- Novartis- $49 billion
- Sinbopharm Group- $42.6 billion
- Roche- $42.2 billion
- Sanofi- $40.66 billion
- Merk- $40.1 billion
- Bayer- $29.1 billion
- Gilead- $26.1 billion
- Nucala is a treatment for asthma. They are currently investigating its usefulness in treating COPD. This has been prescribed to over 30,000 patients in the US. Recently two new self-administration methods were approved so the drug may now be taken at home if deemed appropriate.
- Trelegy Ellipta is an inhaled medication to treat COPD. It is used once a day. It contains "fluticasone furoate, an inhaled corticosteroid, umeclidinium, a long-acting muscarinic antagonist; and vilanterol, a long-acting beta2-adrenergic agonist, delivered in GSK’s Ellipta dry powder inhaler, which is used across the entire new portfolio of inhaled COPD medicines". It has met the goals of a late stage study. A phase three study was recently completed on its treatment of uncontrolled asthma. It showed significant improvement and improved lung function.
- Anoro Ellipta is a combination of two bronchodilators in a dry powder inhaler.
- Breo Ellipta is a once daily treatment for adult asthma patients that is long acting.
- GSK is working a potentially new class of immunothereaphy drugs to treat common cancers. The research is focused around a protein called STING. It can release T-cells into the body to fight off cancer. They are working on a way to activate this protein, and have has some promising results. These molecules could be injected into the bloodstream instead of the tumor. In 2019, they will be progressing to human safety studies. They also see potential for turning this protein off and becoming a treatment for autoimmune diseases like Lupus.
- GSKL is continuing their COPD research and has identified several biomarkers that can be used in trials.
- Tuberculosis (TB) is a top ten cause of death. GSK is closer to finding a new vaccine. GSK has been working for years with Aeras, a non-profit biotech company to develop this. It is in clinical trials (phase 2) and has been tested on high risk areas in Africa. This vaccine can possibly prevent individuals with latent TB from getting pulmonary TB. Results will be available later this year.
- GSK is using "Self Amplifying Messenger RNA (SAM), Adjuvants, Bioconjugates, GMMA (Generalized Modules for Membrane Antigens) and Chad (Chimpanzee adenovirus)" technologies to develop new vaccines. They take part of the RNA code of a virus and make messenger RNA molecules. Once injected into a patient, the cells begin to produce the vaccine. Adjuvant technology enables them to make vaccines that target certain age groups.
- Dovato, a new HIV treatment approach made up of two drugs, was approved by the FDA this year. It is a single tablet medicine that is made up of dolutegravir and lamivudine. This drug has been shown to have the same efficacy as older drugs with less toxicity.
- Zejula from Tesaro has been submitted to the FDA as a possible treatment for advanced "ovarian, fallopian tube, or primary peritoneal cancer patients who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with either the BRCA mutation or Homologous recombination deficiency (HRD) and have progressed more than six months after the last platinum-based chemotherapy." A decision will be made by October 24, 2019.
- Shingrix has been approved to treat shingles in China for patients over 50. This medicine was on a list that China has accepted for expedited approval. It has shown over 90% efficacy rate. It will be available in 2020.
- If approved, ViiV Healthcare's (a part of GSK) new treatment for HIV will be the first ever once-monthly, injectible medication for HIV. It has proven as effective as the oral combination medications in testing on patients with a suppressed viral load. This regime consists of the drugs cabotegravir and rilpivirine.
BETTER HEALTH/ BETTER LIVING INITIATIVES
- Voltaren is a GSK brand that centers around inclusive design. Voltaren is used for osteoarthritis. They have redesigned the package to be easier to hold and open. They have also redesigned Panadol packaging so parents can deliver medicine with one hand.
DIGITAL INITIATIVES (TECHNOLOGY/APPS)
- GSK has a goal of using technology to make sure they are there when the patient needs them. Seventy-five percent of consumers research medications online. GSK is working with retailers and consumers to come up with digital solutions.
- GSK developed a flu tracker in conjunction with their drug Theraflu for the Russian market. It used social information and weather data to identify at risk areas. The app then informed the users and recommended solutions. It was more successful than their attempts to do the same thing on their website.
- GSK partnered with Google to work on in house data management, GSK became the first healthcare company to own their own full tech stack.
- GSK has a digital innovation hub that is global for their business along with an advisory board.
- They have set priorities to upgrade media and change up the media mix/marketing.
- Responsible Health Initiatives a partnership between GSK, Teva, EcoVadis, and Takeda. Their goal is to use technology to improve the global healthy supply chain. Their vision includes improving standards for CSR assessments, adopting a common platform for CSR performance, implementing shared tools, and working together to reduce risk in the supply chain.
- Goals have been set to reach 800 million undeserved people in developing countries by 2025 with their products and to provide 12 million people with healthcare access.
- They strive to be a modern employer that focuses on engaged people, inclusion, diversity, health and well-being.
- GSK operates the Tres Cantos lab that allows international scientists to pursue their own projects. Researchers are able to access GSK's expertise in this collaborative approach to drug discovery.
- The AMR Industry Alliance is a partnership to provide access to antibiotics and vaccines. The goals of this initiative are to ensure the access to these medications is affordable. They have agreed to cap the price of needed medicines at 25% of the cost to a developed country. They want to protect 300 million children by 2024.
- GSK is in a partnership with the University of California. They are establishing a state-of-the-art laboratory for CRISPR (DNA) technologies to study genomic research. They will be working on gene mutations and how they can cause disease. CRISPR allows them to do this on a larger scale than ever thought possible. GSK will spend up to $67 million on this project over the next five years.
- GSK has partnered with Pfizer to create a Consumer Healthcare Joint Venture on December 19, 2018.
- Medicine for Malaria is another GSK initiative to fight one of the oldest diseases known to man. They share there Tres Cantos research facility with other researchers in the malaria community. They have developed a dingle dose "tafenoquine" that has been approved in Australia and the US. It is the first new treatment in 60 years. They will be bringing 10 million doses of RTS, a vaccine, to children in Africa.
- Comic Relief, a UK charity, has partnered with GSK to create an almost $28 million dollar fund to fight malaria. They are supporting 22 community projects in Africa and Asia. So far, they have reached 1.7 million people.
- A partnership with 23andMe that will last four years has been announced recently. They will collaborate in the area of genetic and phenotypic research with a goal of developing new medicines for unmet medical needs. They have set goals to improve target selection groups, identify subgroups that are most likely to respond to treatment, and to find more effective ways to recruit for clinical studies.
- GSW works with Save the Children to prevent child deaths from preventable/treatable diseases. They have goals to improve access to healthcare, training workers in the poorest communities, developing child-friendly medication, and "working for stronger child health policies". They have reached over 2.8 million children.
- Smile Train has partnered with GSK to treat cleft-palate and other orthodontic issues. GSK will provide them with funding.
To select the competitors to GSK we located multiple top lists and SWOT analysis where competitors where listed. They are shared in the sources. After locating the revenue of each pharmaceutical company, we ordered them by revenue.
Please note that there are multiple instances where we used quotes to not detract from the scientific jargon.